Curis Stock Price, News & Analysis

Curis, Inc. (NASDAQ: CRIS) will release its Q2 2022 financial results on August 4, 2022, after the close of U.S. markets. A conference call will be held on the same day at 4:30 pm ET to discuss the results. Investors can dial in or access the call on Curis's website. The company focuses on developing innovative cancer therapeutics, with ongoing trials for its drug emavusertib and partnerships with organizations like Aurigene and Genentech. The FDA has placed a partial clinical hold on certain trials but allows current participants to continue treatment.

Curis, Inc. (NASDAQ: CRIS) announced the grant of 873,750 inducement stock options to 16 new employees, effective July 5, 2022. Each option has an exercise price equal to the closing stock price on that date and vests over four years. This move aims to attract talent and is part of their strategy in developing innovative cancer therapeutics, including ongoing clinical trials for the IRAK4 inhibitor, emavusertib. Curis faces a partial clinical hold on its TakeAim trials, impacting new patient enrollment.

Curis, Inc. (NASDAQ: CRIS) presented novel findings at the 2022 European Hematology Association Congress regarding the IRAK4 inhibitor, emavusertib. The data suggest that nuclear localization of IRAK4 in cancer cells, particularly in acute myeloid leukemia (AML), correlates with better treatment responses. Notably, one patient with primary CNS lymphoma achieved a complete response following emavusertib treatment after prior ibrutinib therapy. The company aims to develop a companion diagnostic for identifying patients most likely to benefit from emavusertib, which is currently undergoing trials for various hematologic malignancies.

Curis, Inc. (NASDAQ: CRIS) presented positive clinical data for emavusertib at the 2022 ASCO Annual Meeting. In the TakeAim Lymphoma study, 8 of 9 evaluable patients achieved tumor reduction, including 2 complete and 2 partial responses. Notably, complete response was observed in a patient with prior ibrutinib treatment, suggesting potential for overcoming ibrutinib resistance. In the TakeAim Leukemia trial, emavusertib showed promising single-agent activity in heavily pretreated AML and HR-MDS patients. The trials are currently under partial clinical hold by the FDA.

Curis, a biotechnology firm listed under NASDAQ: CRIS, will present a company overview at the 2022 Jefferies Healthcare Conference on June 9, 2022, at 11:00 a.m. in New York. James Dentzer, President and CEO, will lead the presentation. A live webcast will be available on the Curis website, with a replay accessible for 90 days post-event. Curis focuses on cancer therapeutics, holding licenses for various innovative treatments, including emavusertib, currently in clinical trials, despite a partial hold by the FDA on certain trials. For more details, visit www.curis.com.

Curis (NASDAQ: CRIS) announces the upcoming presentations of multiple abstracts at the European Hematology Association 2022 Hybrid Congress from June 9-12, 2022, in Vienna. Key data from the TakeAim Lymphoma trial shows early anti-cancer activity with emavusertib combined with ibrutinib in heavily pretreated patients, including one complete response and two partial responses. Additionally, relevant insights from the TakeAim Leukemia study will also be shared. The company highlights the need for new treatment options for patients with resistant hematologic cancers.

Curis, a biotech firm, reported a net loss of $16.1 million for Q1 2022, compared to a loss of $9.9 million in Q1 2021. Revenues remained stable at $2.1 million. The company has a strong balance sheet with $120.7 million in cash, allowing operations to continue into 2024. Clinical updates include promising data for emavusertib, an IRAK4 inhibitor, though FDA has placed a partial hold on two studies. Initial safety data for CI-8993, an anti-VISTA antibody, were also discussed.

Curis, Inc. (NASDAQ: CRIS) will announce its first quarter 2022 financial results on May 5, 2022, after U.S. market close. A conference call is scheduled for the same day at 4:30 pm ET. The call can be accessed by dialing (888) 346-6389 in the U.S. or (412) 317-5252 internationally, and will also be available on Curis's website. Curis focuses on developing cancer therapeutics and has ongoing collaborations with Aurigene, ImmuNext, and Genentech.

Curis, Inc. (NASDAQ: CRIS) announced a partial clinical hold placed by the FDA on its TakeAim Lymphoma study for emavusertib. This follows an earlier hold on the TakeAim Leukemia study, affecting patient enrollment in both studies. Current participants can continue treatment at specified doses, pending reconsent. The FDA requests additional data on safety and efficacy related to emavusertib, including specific safety concerns. Curis aims to resolve this hold and is optimistic about the potential of emavusertib to address unmet needs in B-cell cancers.